

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior version, and listings, of claims in this application:

**Listing of Claims:**

1 (Original). A method of treating a neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of a combination comprising CCI-779 and interferon  $\alpha$ .

2 (Original). The method according to claim 1, wherein the neoplasm is renal cancer.

3 (Withdrawn). The method according to claim 1, wherein the neoplasm is soft tissue sarcoma.

4 (Withdrawn). The method according to claim 1, wherein the neoplasm is breast cancer.

5 (Withdrawn). The method according to claim 1, wherein the neoplasm is a neuroendocrine tumor of the lung.

6 (Withdrawn). The method according to claim 1, wherein the neoplasm is cervical cancer.

7 (Withdrawn). The method according to claim 1, wherein the neoplasm is uterine cancer.

8 (Withdrawn). The method according to claim 1, wherein the neoplasm is a head and neck cancer.

- |                 |  |
|-----------------|--|
| 9 (Withdrawn).  | The method according to claim 1, wherein the neoplasm is glioma.                     |
| 10 (Withdrawn). | The method according to claim 1, wherein the neoplasm is non-small cell lung cancer. |
| 11 (Withdrawn). | The method according to claim 1, wherein the neoplasm is prostate cancer.            |
| 12 (Withdrawn). | The method according to claim 1, wherein the neoplasm is pancreatic cancer.          |
| 13 (Withdrawn). | The method according to claim 1, wherein the neoplasm is lymphoma.                   |
| 14 (Withdrawn). | The method according to claim 1, wherein the neoplasm is melanoma.                   |
| 15 (Withdrawn). | The method according to claim 1, wherein the neoplasm is small cell lung cancer.     |
| 16 (Withdrawn). | The method according to claim 1, wherein the neoplasm is ovarian cancer.             |
| 17 (Withdrawn). | The method according to claim 1, wherein the neoplasm is colon cancer.               |
| 18 (Withdrawn). | The method according to claim 1, wherein the neoplasm is esophageal cancer.          |

19 (Withdrawn). The method according to claim 1, wherein the neoplasm is gastric cancer.

20 (Withdrawn). The method according to claim 1, wherein the neoplasm is leukemia.

21 (Withdrawn). The method according to claim 1, wherein the neoplasm is colorectal cancer.

22 (Withdrawn). The method according to claim 1, wherein the neoplasm is Kaposi's sarcoma.

23 (Withdrawn). The method according to claim 1, wherein the neoplasm is liver cancer.

24 (Withdrawn). The method according to claim 1, wherein the neoplasm is unknown primary cancer.

25 (Original). A method of treating a neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of a combination comprising CCI-779 and interferon  $\alpha$ , wherein either CCI-779, interferon  $\alpha$ , or both are provided in subtherapeutically effective amounts.

26 (Original). An antineoplastic combination which comprises an antineoplastic effective amount of a combination of CCI-779 and interferon  $\alpha$ .

27 (Original). A method of treating a neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of a combination comprising 42-O-(2-hydroxy)ethyl rapamycin and interferon  $\alpha$ .

28 (Original). A pharmaceutical pack containing a course of treatment of a neoplasm for one individual mammal, wherein the pack contains (a) units of CCI-779 and (b) units of interferon  $\alpha$  in unit dosage form.

29 (Original). A pharmaceutical composition useful in treating a neoplasm in a mammal in need thereof, the composition comprising (a) 42-O-(2-hydroxy)ethyl rapamycin in unit dosage form and (b) units of interferon  $\alpha$  in combination or association with a pharmaceutically acceptable carrier.

30 (Original). An antineoplastic combination comprising an antineoplastic effective amount of a combination of 42-O-(2-hydroxy)ethyl rapamycin and interferon  $\alpha$ .